# A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment

> **NCT05865171** · PHASE1 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 16 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** IXP

## Key facts

- **NCT ID:** NCT05865171
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-12
- **Primary completion:** 2024-06-12
- **Final completion:** 2024-06-12
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2024-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05865171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05865171, "A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05865171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*